Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)
Role of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (MNCs) In Patient With Multiple Sclerosis .It is Self Funded (Patients' Own Funding) Clinical Trial
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- BMMNC
What it measured
Main measures
analysis of patients symptoms
baseline and 6 months
Other measures (6)
changes in Expanded Kurtzke Disability Status Score scale
baseline and 6 months
Disability progressionchanges in clinical variables
baseline and 6 months
Quality Of life questionnaire
baseline and 6 months
Quality of life (reported by participants)changes in MRI scan report
baseline and 6 months
MRI lesionschanges in cerebrospinal fluid tests
baseline and 6 months
Blood or spinal fluid markersChanges in analysis of visual evoked potential test
baseline and 6 months
Myelin repair
Who could take part
MS (type not specified) · 18 to 65
Show the full criteria
Inclusion criteria
Confirmed Diagnosis of MS, Aged 18 - 65 years. Duration of disease: >5 years Signed, written informed consent Willing and able to comply with study visits according to protocol for the full study period
Exclusion criteria
* Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results * Patient with any active or chronic infection * No life-threatening organ dysfunction. * Pregnancy or risk of pregnancy. * Patients who are seropositive for HIV1, HIV2, Hepatitis B Surface Antigen, and Hepatitis C * Patients unable to give written informed consent in accordance with research ethics board guidelines * Treatment with any immunosuppressive therapy, including natalizumab and fingolimod, within the 3 months prior to randomization * Treatment with interferon-beta or glatiramer acetate within the 30 days prior to randomization * Treatment with corticosteroids within the 30 days prior to randomization * Current treatment with an investigational therapy
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The aim of this study is to prove the BMMNC Therapy in Multiple sclerosis, and to control symptoms and help to maintain a normal quality of life of suffering patients.
Papers
Loading reviews and guidelines…
History
Started
Jun 2014
Main results due
Nov 2016
Finished
Dec 2016